Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment (Advances in Therapy, (2022), 39, 8, (3501-3521), 10.1007/s12325-022-02166-6)
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 175 KB, PDF-dokument
The authors would like to acknowledge missing data for all prior latanoprost users as a whole. The following sentence has been added to the manuscript (page 8, first paragraph): Mean (SD) reduction from baseline at Month 6 for users of all latanoprost formulations (preserved and PF) was 6.1 (4.25) mmHg (25.9%; p\0.0001). The authors have also prepared a table to summarise the change in intraocular pressure following a switch to the preservative-free tafluprost/timolol fixed-dose combination from all latanoprost formulations (preserved and preservative-free formulations). See Table 1 below.(Table Preseneted.) .The original article has been corrected.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Advances in Therapy |
Vol/bind | 39 |
Udgave nummer | 8 |
Sider (fra-til) | 3522-3523 |
Antal sider | 2 |
ISSN | 0741-238X |
DOI |
|
Status | Udgivet - 2022 |
Bibliografisk note
Publisher Copyright:
© Springer Healthcare Ltd., part of Springer Nature 2022.
ID: 327065633